New research has suggested that a probiotic could improve polycystic ovarian syndrome (PCOS) symptoms.
The study, published in MedScience, investigated the therapeutic potential of Akkermansia muciniphila PROBIO (AP), a specific probiotic strain, in a dehydroepiandrosterone-induced PCOS rat model, revealing significant improvements in reproductive and metabolic parameters through modulation of gut microbiota and enhancement of arginine biosynthesis.
Emerging evidence has increasingly implicated disturbances in the gut microbiota in PCOS pathogenesis, suggesting that probiotic interventions may offer novel therapeutic avenues.
Why this matters
PCOS is one of the most common chronic endocrine and metabolic disorders affecting women of reproductive age, with global prevalence estimates ranging from 5% to 18%.
This condition is characterised by reproductive abnormalities, hormonal imbalances and metabolic dysfunction.
PCOS is a leading cause of female infertility and is often associated with insulin resistance, dyslipidaemia and obesity.
Akkermansia muciniphila has gained recognition as a promising next-generation probiotic due to its demonstrated efficacy in various metabolic disorders, including obesity, type 2 diabetes, cardiovascular disease and non-alcoholic fatty liver disease.
The "mucin-degrading bacterium" exerts beneficial effects through multiple mechanisms, including modulation of the gut microbiota, reinforcement of the intestinal barrier, regulation of immune responses and optimisation of metabolic pathways.
Recent studies have shown decreased abundance of A. muciniphila in both DHEA-induced PCOS mouse models and human patients with PCOS compared with healthy controls.
This suggests a potential pathological role for this bacterium in the disorder.
Study results
The study examined female Sprague-Dawley rats administered dehydroepiandrosterone (DHEA) to induce polycystic ovary syndrome (PCOS) characteristics. The rats received oral gavage of live AP for 35 days, starting two weeks before DHEA exposure.
Results showed that AP treatment significantly reduced PCOS-related abnormalities, including lower serum testosterone, a reduced free androgen index and normalised luteinising hormone (LH) to follicle-stimulating hormone (FSH) ratios.
AP also improved glucose homeostasis, enhancing glucose tolerance and reducing fasting insulin levels without affecting body weight.
Investigations using 16S rRNA gene sequencing and metabolomics revealed that AP improved gut microbiota by increasing beneficial bacteria and decreasing harmful ones, as well as enhancing arginine biosynthesis, leading to higher serum L-arginine levels.
Supplementing L-arginine alone in a separate group of PCOS rats produced similar benefits, demonstrating its role as a key mediator and suggesting the gut microbiota-arginine axis as a new target for PCOS intervention.
The clinical implications of these findings are significant. Current management of polycystic ovary syndrome (PCOS) mainly relies on hormonal contraceptives, insulin sensitisers and lifestyle modifications, with few options for addressing the underlying issues.
This new study reveals that a specific probiotic strain can reverse reproductive and metabolic dysfunction by enhancing L-arginine production.
L-arginine is vital for ovarian function, follicular development and vascular regulation, making it an attractive therapeutic target.
The research also highlights the role of the gut microbiota in PCOS pathogenesis, linking gut microbial composition to reproductive outcomes through arginine biosynthesis. This opens the door for developing microbiota-targeted therapies.
In conclusion, Akkermansia muciniphila PROBIO therapy shows promise in reversing reproductive and metabolic dysfunction in a PCOS rat model.
This establishes a novel therapeutic strategy targeting the gut microbiota-metabolite axis and positions L-arginine as a potential adjunctive treatment for PCOS.